Beta Bytes: Week of October 3rd

Beta Bytes Financial News

Sep 30

The world is preparing to deliver one of the largest mass vaccination campaigns in human history, but managing the process of safely distributing effective COVID-19 vaccines to potentially billions of people will be extremely challenging.
Work.com for Vaccines is meant to help governments and healthcare organizations more safely and efficiently manage vaccine programs at scale.
Additionally, customers of the service will be able to design, build, integrate and manage their vaccine programs end-to-end for quick deployment quickly.

GRAIL was founded by Illumina four years ago as a standalone company and is developing a multi-cancer screening test that is expected to be available for clinical use next year.
Illumina will pay $7.1 billion for this startup company that promises early detection of cancer.
The decision to purchase comes as Illumina recognizes the opportunities provided by cancer testing, and expects there to be a $75 billion-a-year market for it worldwide by 2035.

This device features an integrated X52 5G modem with support for both mmWave and sub-6GHz 5G and improved CPU and graphics performance.
The new chip is effectively a modernized version of the 730G, offering a new Adreno 619 GPU that Qualcomm says offers up to 10 percent better graphics rendering performance.
By replacing the 730G with a 5G variant, the 750G speaks to Qualcomm’s emphasis on making more 5G options available for its partners.

Libra Therapeutics, Inc. launched earlier this week in San Diego, CA with a mission of developing novel drug candidates focused on restoring the cellular balance lost in neurodegenerative diseases.
The Biotech start-up was founded on breakthrough science generated by Axxam S.p.A to provide novel and proprietary chemical matter, cutting edge and exclusive assays, and robust drug discovery expertise.
The financing proceeds will be used primarily to build the team and advance a pipeline of novel small molecule drug candidates for the treatment of neurodegenerative diseases.

Data about pollen levels and content has traditionally been based on 24-hour averages from manual counting stations.
However, pollen peaks at different times in the middle of the day and fluctuates, so it is helpful for those with allergies to know when the levels will be the highest and when to avoid outside activity to prevent symptoms.
To solve this, Pollen Sense launched its app Pollen Wise to offer indexes for several categories of allergens including mold, weeds, trees and grass and tell users how high the pollen levels are in their area, and the levels expected throughout the day.

Market Update: October 5th